Every other entry in this series documents a literature that is thin, indirect, or missing. This one documents the opposite problem. TriHex has the best study designs in cosmetic peptides and some of the smallest samples in medicine, and almost all of it comes from one company.
Searched on 2026-09-11: 29 PubMed records for TriHex, 74 for Alastin. By comparison, the entire indexed record for acetyl tetrapeptide-3 is one paper and for myristoyl pentapeptide-17 it is none.
What it is, and why it is one entry and not two
TriHex is a supplier system of two peptides — tripeptide-1 and hexapeptide-12 — from Alastin Skincare, now a Galderma company. The two are not sold separately and no study separates them, so treating them as one ingredient is not a simplification here; it is the only honest option.
Tripeptide-1 is glycyl-histidyl-lysine: GHK, without a copper ion and without a fatty tail. The site's copper peptide entry covers the metal-bound form and the palmitoyl tripeptide-1 entry covers the palmitoylated form. Three products, one tripeptide, three different cases — and the evidence does not travel between them.
The system's stated rationale is also unusual, and it is the part most worth understanding. The claim is not that the peptides supply collagen. It is that they help clear degraded extracellular matrix material — fragmented collagen and the dystrophic elastin that accumulates with sun exposure — so that the skin's own repair can proceed. That is why the product is positioned around procedures rather than as a daily wrinkle cream: the marketing and the trials both treat it as preparation and recovery.
The designs are real, and so are the sample sizes
The flagship study is Widgerow et al., Journal of Cosmetic Dermatology, December 2025 (PMID 41358458): prospective, randomised, double-blind, split-face, treatment against vehicle, in patients undergoing elective facelift surgery, with baseline biopsies four weeks before surgery and the excised skin from each side analysed afterwards by an independent dermatopathologist.
Read that design list again. Randomisation, double-blinding, a vehicle control, each patient serving as their own control, and a histological endpoint from tissue that was going to be removed anyway. This is close to the best study that can ethically be run on a cosmetic product, and it is a standard the rest of this category does not come near — the SNAP-8 and Argireline entries document what the usual evidence looks like.
It enrolled five patients.
Five is enough to demonstrate that a biological change occurs and far too few to estimate how often, in whom, or how much. The paper reports histological differences described as significant, with matrix changes evident only on the treated side. Two limits belong beside that. The product tested was Nectar 2.0, reformulated to add octapeptide-45, so it is not a test of the two TriHex peptides alone. And four of the six authors are employees of Alastin Skincare.
The solar elastosis claim, and the funnel underneath it
The boldest paper is Widgerow, Napekoski, Shafiq and Robison, Journal of Cosmetic Dermatology, April 2026, titled TriHex Technology and Reversal of Solar Elastosis: Dispelling Some Myths (PMID 41918136). Its conclusion is that solar elastosis — long taught as the irreversible endpoint of sun damage — is reversible, and that the peptide system reverses it.
The numbers in its own methods section are worth laying out in order, because the headline figure is not drawn from the largest of them.
| Stage | Count |
|---|---|
| Patients across the pooled clinical studies | 624 |
| Biopsies | 80 |
| Cases with reported solar elastosis | 31 |
| Share of reported histology showing clear reversal | 74% |
The 74% describes the histology reported within the 31-case subset. It is not 74% of 624 patients, and a summary that carries the percentage without the funnel makes the claim sound roughly twenty times better supported than it is.
The design word that matters is retrospective. This is a pooled re-reading of studies already run, not a prospective test of the hypothesis it concludes. And the conflict statement is unusually clear, to the authors' credit: three of four authors are Alastin employees, and every clinical trial included in this retrospective review was funded by Alastin Skincare, A Galderma Company.
None of that makes the histology wrong. New elastin and collagen on a Herovici or Movat stain is a hard finding, much harder than the satisfaction scores that carry most of this category. It means the finding awaits someone outside the company repeating it.
The one genuinely independent result
There is one, and it is the most interesting paper here.
Ligorio et al., ACS Applied Bio Materials, March 2025 (PMID 39964201), from the University of Nottingham, Binghamton University and a research group at Estée Lauder, declaring no competing financial interest. The subject is palmitoyl hexapeptide-12, and the method is orbital-trapping secondary ion mass spectrometry on full-thickness human skin.
What it found: the peptide permeates both the stratum corneum and the epidermal layers, and once through it self-assembles into a gel by harnessing ions already present in the skin. The authors then showed it strengthening and repairing the barrier after the skin had been stripped of lipids, measured mechanically and by stimulated Raman scattering.
The penetration question is the one this whole ingredient category usually cannot answer. Peptides are large and charged, the barrier is built to exclude exactly that, and the standard move in cosmetic marketing is to assume the problem away. Here it was measured, in human skin, by a group with nothing to sell.
Two honest qualifications. The molecule studied is the palmitoylated form, and TriHex lists hexapeptide-12 without that tail — and a fatty tail is precisely the variable that decides penetration, which is why this site treats palmitoylated and unpalmitoylated forms as different ingredients everywhere else. And demonstrating that a molecule gets in is not demonstrating that it improves an appearance.
Where the safety evidence actually sits
A 2026 paper in Current Research in Toxicology from Procter & Gamble researchers (PMID 41953401) reviews how cosmetic peptides have historically been evaluated for safety and proposes a framework of six bioinformatic tools to replace animal testing, validating it on a set that includes palmitoyl hexapeptide-12 and palmitoyl pentapeptide-4 alongside known toxins.
It is a useful document for a reader of any of these entries, because it makes plain that safety substantiation for this ingredient class is a live methodological question rather than a settled one, and that the numbered synthetic peptides have not been through the kind of assessment the older protein-derived cosmetic ingredients received.
What the evidence does not show
No trial by anyone other than the manufacturer or its funded investigators. No study isolating tripeptide-1 from hexapeptide-12. No trial of the system for everyday ageing outside a procedure context with an instrumented wrinkle endpoint. No prospective test of the solar elastosis reversal claim. No penetration data for hexapeptide-12 in the unpalmitoylated form the product actually lists. And, as everywhere in this category, no disclosed concentration.
Sources and dates
Opened 2026-09-11: PubMed E-utilities counts for TriHex (29 records), Alastin (74), hexapeptide-12 (5) and tripeptide-1 in title or abstract (33), with the combined TriHex and Alastin result set retrieved and read by title; full abstracts, author affiliations and conflict-of-interest statements of PMID 41358458 (Widgerow et al. 2025), PMID 41918136 (Widgerow et al. 2026), PMID 39964201 (Ligorio et al. 2025) and PMID 41953401 (Bjerke et al. 2026). The patient-to-biopsy funnel table was compiled from the figures stated in the 2026 paper's own methods and results. Corrections go to the contact page; the review standard is on the testing notes page.